Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).

@article{Barouch2013CharacterizationOH,
  title={Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).},
  author={Dan H Barouch and Jinyan Liu and Lauren E. Peter and Peter Abbink and M. Justin Iampietro and Ann Cheung and Galit Alter and Amy Chung and Anne-Sophie Dugast and Nicole Frahm and M Juliana McElrath and Holger Wenschuh and Ulf Reimer and Michael S. Seaman and Maria Grazia Pau and Mo E. M. Weijtens and Jaap Goudsmit and Stephen R. Walsh and Raphael Dolin and Lindsey Robert Baden},
  journal={The Journal of infectious diseases},
  year={2013},
  volume={207 2},
  pages={248-56}
}
BACKGROUND Adenovirus serotype 26 (Ad26) has been developed as a novel candidate vaccine vector for human immunodeficiency virus type 1 (HIV-1) and other pathogens. The primary safety and immunogenicity data from the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) 001 trial, the first-in-human evaluation of a prototype Ad26 vector-based vaccine expressing clade A HIV-1 Env (Ad26.ENVA.01), are reported concurrently with this article. Here, we characterize in greater… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
22 Citations
41 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Similar Papers

Loading similar papers…